Robin Kramer Net Worth

The estimated Net Worth of Robin Kramer is at least $1.45 Million dollars as of 16 February 2024. Ms. Kramer owns over 1,345 units of Biogen Inc stock worth over $1,264,819 and over the last 8 years she sold BIIB stock worth over $183,073. In addition, she makes $0 as Chief Accounting Officer and Vice President at Biogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Kramer BIIB stock SEC Form 4 insiders trading

Robin has made over 20 trades of the Biogen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 1,345 units of BIIB stock worth $267,776 on 16 February 2024.

The largest trade she's ever made was exercising 14,503 units of Biogen Inc stock on 2 March 2018 worth over $2,887,402. On average, Robin trades about 819 units every 62 days since 2017. As of 16 February 2024 she still owns at least 6,353 units of Biogen Inc stock.

You can see the complete history of Ms. Kramer stock trades at the bottom of the page.

Robin Kramer biography

Robin C. Kramer has been appointed as Chief Accounting Officer, Vice President of the Company. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007, Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Anderson LLP. Ms. Kramer is a licensed certified public accountant (CPA) in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs and served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015.

What's Robin Kramer's mailing address?

Robin's mailing address filed with the SEC is 5005, McConnell Avenue, Del Rey, Los Angeles, Los Angeles County, California, 90066, United States.

Insiders trading at Biogen Inc

Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.

What does Biogen Inc do?

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Complete history of Ms. Kramer stock trades at Biogen Inc, Hertz Global, and Armata Pharmaceuticals Inc

Biogen Inc executives and stock owners

Biogen Inc executives and other stock owners filed with the SEC include:

• Michel Vounatsos,
  Chief Executive Officer, Director
• Susan Alexander,
  Executive Vice President, Chief Legal Officer and Secretary
• Alfred Sandrock,
  Executive Vice President, Research and Development, Chief Medical Officer
• Chirfi Guindo,
  Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
• Michel Vounatsos,
  CEO & Director
• Susan H. Alexander Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Susan H. Alexander,
  Exec. VP, Chief Legal Officer & Sec.
• Michael R. McDonnell,
  Exec. VP & CFO
• Chirfi Guindo,
  Exec. VP of Global Product Strategy & Commercialization
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Robert Pangia,
  Independent Director
• Brian Posner,
  Independent Director
• Alexander Denner,
  Independent Director
• Nancy Leaming,
  Independent Director
• Caroline Dorsa,
  Independent Director
• Stephen Sherwin,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Richard Mulligan,
  Independent Director
• Jesus Mantas,
  Independent Director
• William Hawkins,
  Independent Director
• Robin Kramer,
  Chief Accounting Officer, Vice President
• Daniel Karp,
  Executive Vice President, Corporate Development
• Alphonse Galdes,
  Executive Vice President, Pharmaceutical Operations and Technology
• Ginger Gregory,
  Chief Human Resource Officer, Executive Vice President
• Michael McDonnell,
  Chief Financial Officer, Executive Vice President
• Dr. Sanjay Jariwala,
  Sr. VP of Worldwide Medical
• Nicole Murphy,
  Head of Pharmaceutical Operations & Technology
• Dr. Anabella Villalobos Ph.D.,
  Sr. VP of Biotherapeutic & Medicinal Sciences
• Dr. Alphonse Galdes,
  Exec. VP of Pharmaceutical Operations & Technology
• Dr. Ginger Gregory,
  Exec. VP & Chief HR Officer
• Natacha Gassenbach,
  Chief Communication Officer & Head of Corp. Affairs
• Michael Hencke,
  Director of Investor Relations
• Mark J. Hernon,
  Sr. VP & Chief Information Officer
• Robin C. Kramer,
  Sr. VP & Chief Accounting Officer
• George A Scangos,
  Chief Executive Officer
• Adriana Karaboutis,
  EVP, Tech. and Bus. Solutions
• Michael D Ehlers,
  EVP, Research and Development
• Gregory F Covino,
  VP, Chief Accounting Officer
• Lynn Schenk,
  Director
• Paul Mc Kenzie,
  EVP Pharmaceutical Oper & Tech
• Paul J Clancy,
  CFO
• Kenneth Di Pietro,
  EVP Human Resources
• Adam Koppel,
  SVP, Chief Strategy Officer
• Susan Langer,
  Director
• Jean Paul Kress,
  EVP Pres Int'l & Global Hd GTO
• Priya Singhal,
  Head of Development
• Jeffrey D Capello,
  EVP & Chief Financial Officer
• Monish D Patolawala,
  Director
• Phillip A Sharp,
  Director
• Steven H Holtzman,
  EVP Corp Devel and Strategy
• John Cox,
  EVP Pharmaceutical Oper & Tech
• Spyridon Artavanis Tsakonas,
  SVP, Chief Scientific Officer
• William Young,
  Director
• Raymond Pawlicki,
  SVP, Chief Information Officer
• Stuart A Kingsley,
  EVP, Global Comm. Operations
• Douglas E Williams,
  EVP Research & Development
• Craig Eric Schneier,
  EVP, Human Resources
• Robert E. Gagnon,
  Chief Acct Officer VP & Contr
• Francesco Granata,
  EVP Global Commercial Operatio
• James C Mullen,
  CEO and President
• Michael F Mac Lean,
  SVP, Chief Accounting Officer
• Bruce Ross,
  Director
• Robert A Hamm,
  SVP, Immunology Business Unit
• Cecil B Pickett,
  President, R & D
• Marijn E Dekkers,
  Director
• Lawrence C Best,
  Director
• Faheem Hasnain,
  SVP, Oncology SBU
• Hans Peter Hasler,
  SVP, International
• Mark C Wiggins,
  EVP - Business Development
• Michael Lytton,
  EVP Corporate & Business Devel
• Alan Glassberg,
  Director
• John Michael Dunn,
  EVP - New Ventures
• Michael Gilman,
  EVP - Research
• Thomas J Bucknum,
  EVP. General Counsel, Sec.
• Nabil Hanna,
  EVP, Research
• William H Rastetter,
  Executive Chairman
• William R Rohn,
  Exec VP & COO
• Sylvie L Gregoire,
  EVP, Bus. Dev & Program Mgmt.
• Burt A Adelman,
  EVP, Development
• Alan Belzer,
  Director
• Michael Kowolenko,
  SVP, Pharm Ops & Technology
• Peter N Kellogg,
  Executive Vice President, CFO
• Mary L Good,
  Director
• Thomas F Keller,
  Director
• Connie Matsui,
  Sr V P, Planning& Resource Dev
• Christopher Viehbacher,
  President and CEO
• Maria C Freire,
  Director
• William D /Ca/ Jones,
  Director
• Nicole Murphy,
  Head of Pharm Ops and Tech
• Rachid Izzar,
  Head of Global Product Strat.
• Adam Keeney,
  Head of Corporate Development
• Jane Grogan,
  Head of Research